Trial Condition(s):
Treatment of venous thromboembolism in cancer patients
A study to gather information about rivaroxaban in patients in the United Kingdom who have cancer and thrombosis (OSCAR—UK)
Bayer Identifier:
22020
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
Patients with cancer are more likely than those without cancer to develop blood clots (deep vein thrombosis and pulmonary embolism), which are treated using blood thinners (anticoagulants). When clots occur, cancer patients carry a higher risk of recurring clots and more likely to bleed on blood thinning treatments. Therefore, it is critical to use blood thinners that optimize the safety and benefits.
There are two main types of blood thinners that are recommended. The tablets which are direct-acting oral anticoagulants and the injections (low molecular-weight heparin). Clinical trials show the tablets may reduce clot risk but may potentially lead to more frequent bleeding, particularly in those with certain risk factors such as stomach ulcers, previous bleeding problems, certain cancer type.
We aim to examine the effectiveness and safety of the tablets versus the injections for treatment of clots in cancer patients, to better understand these treatments' benefits and risks.
Inclusion Criteria
- Be ≥18 years of age at the time of anticoagulation initiation - Have active cancer and acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE) - Treated with rivaroxaban (or any DOAC) or LMWH as their first recorded anticoagulant prescription 7 to 30 days post-acute CAT event diagnosis - Have been active in the data set for at least 12-months prior to the index event and had at least one provider visit in the 12-months prior to the acute VTE event
Exclusion Criteria
- Evidence of atrial fibrillation, recent hip/knee replacement (with 90 days of CAT), ongoing VTE treatment, valvular heart disease defined as any rheumatic heart disease, mitral stenosis or mitral valve repair/replacement - History of inferior vena cava filter before cohort entry - vitamin K antagonist (VKA) use between cohort entry and index day (initiation of DOAC or LMWH) - Evidence of any type of therapeutic anticoagulation use during all available look-back period per written prescription or patient self-report - Initiation of rivaroxaban or other DOACs or LMWH during the study period at non-therapeutic doses (e.g., enoxaparin at a dose other than 1 mg/kg twice daily or 1.5 mg/kg once daily; dalteparin at a dose other than 200 IU/kg of total body weight) - Pregnancy - Recording indicative of palliative care before cohort entry - Any clinically-relevant bleeding-related d hospitalization or VTE recurrence between the initial CAT and the start of observation
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Many locations Many locations, United Kingdom | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Trial Design
Observational Studies in Cancer Associated Thrombosis for Rivaroxaban – United Kingdom Cohort (OSCAR—UK)
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
Other
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- The risk of recurrent VTE at 3-monthsTimeframe: Retrospective data analysis from 2013 to 2020
- Composite of any major bleeding or clinically-relevant non-major bleeding-related hospitalization at 3-monthsPer the International Society on Thrombosis and Haemostasis (ISTH) criteria [9, 10] for identification of bleeding-associated hospitalizations.Timeframe: Retrospective data analysis from 2013 to 2020
- All-cause mortality at 3-monthsTimeframe: Retrospective data analysis from 2013 to 2020
Secondary Outcome
- Recurrent VTE at 6- and 12-months post-index VTETimeframe: Retrospective data analysis from 2013 to 2020
- Composite of any major or clinically-relevant non-major bleeding-related hospitalization at 6- and 12-months post-index VTEIncluding: - Intracranial hemorrhage (ICH) - Critical organ bleeding (e.g., intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial bleeding or intramuscular with compartment syndrome) - Extracranial bleeding-related hospitalizations (including trauma-related)Timeframe: Retrospective data analysis from 2013 to 2020
- Composite of any major bleeding or clinically-relevant non-major bleeding-related hospitalization at 6 and 12-monthsPer the ISTH criteria [9, 10] for identification of bleeding-associated hospitalizations.Timeframe: Retrospective data analysis from 2013 to 2020
- Intracranial hemorrhage (ICH), critical organ bleeding and extracranial bleeding-related hospitalizations as separate outcomesTimeframe: Retrospective data analysis from 2013 to 2020
- All-cause mortality at 6- and 12-monthsTimeframe: Retrospective data analysis from 2013 to 2020
- Incidence rates of recurrent VTE in rivaroxaban, DOAC and LMWH patients experiencing cancer-associated thrombosis (CAT) regardless of the bleeding risk associated with cancer typeTimeframe: Retrospective data analysis from 2013 to 2020
- Any clinically-relevant bleeding-related hospitalization in rivaroxaban, DOAC and LMWH patients experiencing cancer-associated thrombosis (CAT) regardless of the bleeding risk associated with cancer typeTimeframe: Retrospective data analysis from 2013 to 2020
- All cause-mortality in rivaroxaban, DOAC and LMWH patients experiencing cancer-associated thrombosis (CAT) regardless of the bleeding risk associated with cancer typeTimeframe: Retrospective data analysis from 2013 to 2020
- Duration of anticoagulation treatmentTimeframe: Retrospective data analysis from 2013 to 2020
- Discontinuation rates of rivaroxaban, DOAC and LMWH at 3-, 6-, 12-months and all available follow-upTimeframe: Retrospective data analysis from 2013 to 2020
Additional Information
Copyright © Bayer
Powered by
